1 asset in Malignant Atrophic Papulosis

Therapeutic assets addressing Malignant Atrophic Papulosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ruxolitinib Malignant Atrophic Papulosis	National Heart, Lung, and Blood Institute (NHLBI)	P1/2	CCC (52)